GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » Earnings per Share (Diluted)

Zura Bio (Zura Bio) Earnings per Share (Diluted) : $-1.65 (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Earnings per Share (Diluted)?

Zura Bio's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.02. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.65.

Zura Bio's EPS (Basic) for the three months ended in Mar. 2024 was $-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.38.

Zura Bio's EPS without NRI for the three months ended in Mar. 2024 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.67.


Zura Bio Earnings per Share (Diluted) Historical Data

The historical data trend for Zura Bio's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio Earnings per Share (Diluted) Chart

Zura Bio Annual Data
Trend Dec21 Mar22 Dec23
Earnings per Share (Diluted)
- - -2.09

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.76 -1.31 -0.18 -0.14 -0.02

Competitive Comparison of Zura Bio's Earnings per Share (Diluted)

For the Biotechnology subindustry, Zura Bio's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zura Bio's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zura Bio's PE Ratio distribution charts can be found below:

* The bar in red indicates where Zura Bio's PE Ratio falls into.



Zura Bio Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Zura Bio's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-60.36-0)/33.064
=-1.83

Zura Bio's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-7.747-0)/46.915
=-0.17

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Zura Bio  (NAS:ZURA) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Zura Bio Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Zura Bio's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Zura Bio (Zura Bio) Business Description

Industry
Traded in Other Exchanges
Address
4225 Executive Square, Suite 600, La Jolla, CA, USA, 92037
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
Executives
Parvinder Thiara director, 10 percent owner C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Amit Munshi director C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Graham Neil Murray Hamilton director 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Sandeep Chidambar Kulkarni director 92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kimberly Ann Davis officer: Secretary and General Counsel C/O ZURA BIO INC., 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Gary Whale officer: EVP and CTO 2 THE BEACHES, SHIPLAKE, HENLEY-ON-THAMES, OXFORDSHIRE X0 RG9 3BT
Theresa Lowry officer: EVP and CHRO 3629 VILLA TERRACE, SAN DIEGO CA 92104
Michael Howell officer: SVP, Translational Medicine 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Hana Immunotherapeutics Llc 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Chris Kim 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Ewon Comfortech Co., Ltd. 10 percent owner 8, CHEOMDAN 1-RO, JEONGUP-SI, JEONLABUK-DO M5 320836
Steven J Schoch director 2748 BUSH STREET, SAN FRANCISCO CA 94115
Preston Klassen officer: President and COO 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christopher Cabell officer: EVP and CMO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105